Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN203
- Development stage
- Unknown
- Lead developer
- KeyNeurotek Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KN203 is a small molecule µ-opioid receptor (MOR) agonist that was developed by KeyNeurotek Pharma GmbH for the treatment of overactive bladder (OAB) and urgency-frequency syndrome. It was the first compound in its class to be specifically investigated for OAB, operating through the activation of µ-opioid receptors to modulate bladder muscle contraction. The drug reached Phase 2 clinical development, where it was evaluated in a double-blind, randomized, placebo-controlled proof-of-concept trial involving German women with OAB. However, development ceased following the dissolution of KeyNeurotek Pharma.
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on KN203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN203.